Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Petrochemical non-alcoholic fatty liver and insulin resistance

The latest Journal of the American Medical Association shows that the usual recommended measures for treating metabolic syndrome may have only limited efficacy in petrochemical-related nonalcoholic fatty liver disease.

News image

fiogf49gjkf04

Insulin resistance and features of the metabolic syndrome are often associated with nonalcoholic fatty liver disease

Insulin resistance has been considered to be essential for the development of nonalcoholic fatty liver disease.

However, multiple mechanisms are involved in the pathogenesis of nonalcoholic fatty liver disease.

Dr Helma Cotrim and colleagues previously described a form of nonalcoholic fatty liver disease among petrochemical workers.

The investigators noted that predominantly younger men were affected, causing mild fibrosis and cholestasis.

In the current study the team evaluated the relationship of insulin resistance to nonalcoholic fatty liver disease among petrochemical workers.

Most of the patients had no evidence of insulin resistance or metabolic risk factors
Journal of the American Medical Association

The investigators included 40 petrochemical workers with the diagnosis of nonalcoholic fatty liver disease.

The participants presented with abnormal alanine aminotransferase, aspartate aminotransferase, and -glutamyltransferase levels on 3 or more determinations.

The patients were referred to the Hepatology Clinic, Federal University of Bahia, Brazil, between 2001 and 2003.

All had a history of occupational exposure to chemicals including benzene, xylene, ethylene, dimethylformamide, and vinyl chloride for at least 5 years.

Patients, corroborated by family members, indicated the absence of significant ethanol consumption.

The researchers excluded those with use of other drugs and presence of hepatitis B and C virus, hemochromatosis, and autoimmune diseases.

Insulin resistance was determined by the homeostasis model assessment (HOMA) index.

Control HOMA-insulin resistance values were obtained from 63 healthy volunteers.

The team considered insulin resistance to be present when the HOMA index value was 3 or higher.

The cut-off point was validated against the results of the quantitative insulin sensitivity check index.

The concordance between HOMA and quantitative insulin sensitivity check index was 100%.

The investigators found that insulin resistance was absent in 73% of the patients with nonalcoholic fatty liver disease.

Among the 11 patients with insulin resistance, all had hyperlipidemia, while 55% were obese, 73% were overweight, and 45% had diabetes.

The team noted that among 29 patients without insulin resistance, 35% had hyperlipidemia and 27% were also overweight, but without central obesity.

Hyperlipidemia, obesity, overweight, or diabetes were not observed in 38% of the patients.

Liver biopsy was performed on 80% of the patients.

The investigators detected steatohepatitis with fibrosis in 69% of these patients.

The investigative team also noted that 77% of the patients did not have insulin resistance.

All 5 patients with insulin resistance had steatohepatitis with fibrosis.

Dr Cotrim's team concluded, “To our knowledge, this is the first study to evaluate insulin resistance in patients with nonalcoholic fatty liver disease related to chemical exposure.”

“The majority of patients did not have evidence of insulin resistance or metabolic risk factors.”

“These results indicate that, contrary to prior assumptions, the development of fatty liver is not invariably associated with insulin resistance, and other mechanisms may be involved.”

“The absence of demonstrable insulin resistance may explain that this type of nonalcoholic fatty liver disease, usually asymptomatic, presents with mild histological findings that usually improve after workers are removed from exposure.”

“These findings suggest that the usual recommended measures for treating metabolic syndrome, such as diet and exercise, may have only limited efficacy in petrochemical-related nonalcoholic fatty liver disease.”

“However, the natural history of this form of nonalcoholic fatty liver disease and its relationship with co-existing metabolic syndrome deserves further investigation.”

JAMA 2005: 294(13): 1618-20
10 October 2005

Go to top of page Email this page Email this page to a colleague

 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Sexual functioning in Hep C
 02 November 2017 
Rural residence and risk of IBD
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us